Kornimate/medical-research-clean huggingface dataset:
wide awake surgery for tendon repair in hand trauma

Conditions: Tendon Injury - Hand

Summary: wide awake surgery for tendon repair in hand trauma to compare the functional outecomes in terms of active range of motion for tendon repair surgeries performed under wide awake anaesthesia versus general anaesthesia.

all patients aged 15 or above with hand trauma resulting in tendon injuries were included.65 patients undergoing tendon repair in wide awake anaesthesia were grouped as approach arm and another 65 patients of general anaesthesia group were kept as control arm.range of motion of corresponding tendons were measured at completion of sixth postoperative week using goniometer.total active range of motion were calculated according to criteria given by strickland method and american society for surgery ofthe hand (assh). functional outcomes were compared among two groups.

Eligibility criteria:
inclusion criteria: 1. patients of either gender of age 15 years or above. 2. all of the patients with hand injuries with tendon repair required, operated within the hospital premises exclusion criteria: 1. patients allergic to agents of local anesthesia. 2. patients with anxiety symptoms 3. patients with mental disorders rendering them unable to comprehend and follow intraoperative commands. 4. patients with associated nerve injuries. 5. patients requiring bone fixation or with other complex injuries and with soft tissue loss requiring coverage. 6. patients with massive contamination, crush injuries or infection which needs to be addressed and treated prior to definitive repair.
survey among healthcare professionals and ms patients to assess their understanding of rmp materials

Conditions: Multiple Sclerosis

Summary: survey to be completed independently by hcps (neurologists treating patients with ms and ms specialist nurses) and patients/caregivers.

the survey- based study is conducting amongst hcps and patients/caregivers in selected european countries including germany, netherlands, nordics (denmark, sweden), spain and croatia, plus canada, to evaluate whether hcps and patients/caregivers receive the educational materials and to capture their knowledge of specific mayzent (siponimod) safety measures.

Eligibility criteria:
inclusion criteria: physicians will be considered eligible for the survey if they meet the following screening criteria: * care for relapsing ms (rms) patients * personally prescribed disease modifying therapies to ms patients, and; * have prescribed mayzent (siponimod) in at least 1 spms patient. nurses will be considered eligible for the survey if they: * provide supportive care for rms patients * have initiated and/or managed the use of mayzent (siponimod) in at least 1 spms patient. patient inclusion criteria include: - have been initiated onto mayzent (siponimod) to treat their ms since reimbursement exclusion criteria: -

Keywords: multiple sclerosis ms nis survey
transcutaneous oxygen pressure (tcpo2) determination.

Conditions: Peripheral Arterial Diseases

Summary: upper limb arterial disease is a rare condition compared to lower limb arterial disease. in the lower limb, chronic limb ischemia (cli) is characterized by an intractable pain or an ulceration present for at least 2 weeks. guidelines recommend to use transcutaneous oxygen pressure (tcpo2) measurement when a cli is suspected to establish diagnostic with a threshold of 30 mmhg when ankle and toe systolic pressure are not available. in the upper limb, there is no guideline to define cli. when there is a wound preventing finger pressure measurement, tcpo2 is theoretically indicated. however, there is neither standardized site to measure nor threshold value of tcpo2. the investigators hypothesized that normal tcpo2 may be different in the upper limb and that threshold value for cli may also be different compared to lower limb. the investigators planned a study with two parts: 1. prospective study of normal tcpo2 value in healthy volunteers 2. retrospective analysis of patients with upper limb arterial disease to approach the tcpo2 threshold of cli allowing healing in upper limb


Eligibility criteria:
healthy volunteers part: inclusion criteria: * healthy volunteer without upper limb arterial disease * absence of opposition * affiliated to social insurance exclusion criteria: * under 18 yrs old * under law protection * pregnancy retrospective patients part: inclusion criteria: * patients with a tcpo2 measurement available for the upper limb * patients with a follow-up of at least 3 months available * absence of opposition * affiliated to social insurance exclusion criteria: * under 18 yrs old * under law protection * pregnancy

Keywords: transcutaneous oxygen pressure peripheral arterial disease chronic limb ischemia
the effects of oscillating-rotating electric toothbrushes on plaque and gingival health

Conditions: Gingivitis; Plaque

Summary: the aim of this analysis was to compare the effects of oscillating-rotating (o-r), side-to-side (sonic), and manual toothbrushes on plaque and gingival health after multiple uses.


Eligibility criteria:
subjects were excluded from this study for the following reasons; * pregnancy, * rampant caries, * severe periodontitis, * at discretionary of the principal investigator.
evaluate the safety, tolerability and pk of different formulations of orally administered solabegron in healthy male subjects

Conditions: Healthy Subjects, Overactive Bladder

Summary: the purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of different formulations of orally administered solabegron in healthy male subjects.

the purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of different formulations of orally administered solabegron in healthy male subjects. eligible male subjects will be enrolled into 2 cohorts of 12 subjects each conducted in parallel. the study is a single blind (subjects), randomized, cross-over design in 3 study periods.

Eligibility criteria:
inclusion criteria: * body weight greater than or equal to 50 kg, inclusive, and body mass index (bmi) 18.0 - 32.0 kg/m2, inclusive * in good general health as determined by a thorough medical history and physical examination, ecg, vital signs, and clinical laboratory evaluation. results of clinical laboratory tests must be without clinically significant abnormalities, including hematology, clinical chemistry and urinalysis. * adequate venous access to allow for repeated blood sampling * ability to understand and comply with the study requirements * provide written informed consent prior to any study procedure being performed (all subjects should be able to understand the informed consent form and any other documents that subjects are required to read). exclusion criteria: * any clinically relevant abnormality identified on the screening physical examination, clinical laboratory tests, 12-lead ecg, or any other medical condition or circumstance which would make the subject unsuitable for participation in the study based on the investigator's assessment * resting heart rate greater than or equal to 100 beats per minute (bpm) after 5 minutes rest (as above) at the screening visit * qtcf interval (fredericia's correction factor) greater than 450 msec (males subjects) at screening * history of drug or other allergy, which, in the opinion of the investigator, contraindicates their participation * history of smoking, including e-cigarettes, within 3 months of the study and/or a positive urine cotinine at screening * regular alcohol consumption averaging ≥ 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of the first dose of study medication. * positive urine drug or alcohol test at screening * any other condition and/or situation that causes the investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures)

Keywords: overactive bladder, incontinence
effects of peanut intake on cognitive functions

Conditions: Cognition; Inflammation

Summary: the study will test the effects of peanuts on task-related brain activation and cognitive functions in older adults with memory complaints.

the purpose of the study is to determine the effects of peanuts on cognitive performance and task-related brain activation on functional magnetic resonance imaging (fmri) in older adults. the specific aim of the study is to explore the neuroprotective effects of a peanut-enriched diet (2-3 oz of peanuts to replace 20% of the total energy of the habitual diet) for 12 weeks compared to a peanut-excluded habitual diet in elderly men and women with increased risk for cvd and self-reported memory complaints. the study population is older adults 60-80 years in age.

Eligibility criteria:
inclusion criteria: * non-demented elderly between 60-80 years of age * self-reported memory complaints * two cardiovascular risk factors * stable weight for at least 6 months prior to recruitment exclusion criteria: * peanut allergy * smoker * endocrine, metabolic and neuropsychological disorders * ineligible to get an mri * consuming more than 3 servings/week of nuts including peanuts

Keywords: peanuts cognition inflammation oxidative stress
a study of nivolumab in combination with ipilimumab in participants with advanced hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: the main purpose of this study is to compare the overall survival (os) of nivolumab plus ipilimumab versus standard of care (soc) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (hcc) who have not received prior systemic therapy.


Eligibility criteria:
inclusion criteria: * participants must have a diagnosis of hcc based on histological confirmation * participants must have an advanced hcc * participants must have at least one response evaluation criteria in solid tumors (recist) 1.1 measurable previously untreated lesion * child-pugh score 5 or 6 * eastern cooperative oncology group (ecog) performance status(ps) 0 or 1 exclusion criteria: * known fibrolamellar hcc, sarcomatoid hcc, or mixed cholangiocarcinoma and hcc * prior liver transplant * episodes of hepatic encephalopathy (greater than or equal to \[\>=\] grade 2) within 12 months prior to randomization * active brain metastases or leptomeningeal metastases other protocol-defined inclusion/exclusion criteria apply.
an extension study of peak trial

Conditions: Diabetes Mellitus, Type 2

Summary: double blind, three arm, comparative intervention trial for 24 weeks(peak study) with open label extension trial for 28 weeks followed by 2 year observational study.

peak trial is now undergoing (multicenter, randomized, double blind, three-arm parallel group study to evaluate efficacy and safety of alogliptin and pioglitazone combination therapy on glucose control in type 2 diabetes subjects who have inadequate control with metformin monotherapy in korea, takeda no. alo-iit-012). duration of combination treatment is 24 week in the peak trial. long-term efficacy and safety of alogliptin + pioglitazone + metformin combination therapy is not defined in korea yet. thus, extension of the peak trial for the longer treatment upto 1 year has been planned. peak trial will be followed by another 28 week open-label treatment of the same drug as initial randomization (total duration of treatment as randomized 52 week), and followed by 2 year of observation. during observation period, any antidiabetic medication can be added/changed when hba1c of the subject is off target 7% with clinician's clinical decision. after 3 years of initial randomization, durability of glucose control will be assessed between 3 treatment group.

Eligibility criteria:
inclusion criteria: * completed "alo-iit-012(peak study)", without major protocol deviations. * male, or female, 19 years to 75 years. * female with childbearing potential who has a negative urine pregnancy test result at study start and willing to continue practice appropriate birth control during the entire duration of study * subjects completed peak can be included within 30 days after end of the study * subjects completed peak can be included if their treatment is the same as randomized even after 30 days of end of the study. exclusion criteria: * egfr(epidermal growth factor receptor) \< 50ml/min * ast(aspartate aminotransferase)/alt(alanine aminotransaminase) \>2.5 upper limit of normal * pregnant or lactating women * subject who the investigator deems inappropriate to participate in this study * patients with a history of bladder cancer or patients with active bladder cancer * patients with uninvestigated macroscopic hematuria * patients with cardiac failure or a history of cardiac failure (new york heart association \[nyha\] stages 3 to 4) * patients with genetic problems such as galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption, since this study drug contains lactose
high protein oral nutritional support with special nutrients in patients with type 2 diabetes and foot ulcer

Conditions: Healing Ulcer

Summary: to assess the supplement of a high protein oral nutritional supplement enriched with arginin, zink, vitamin c and antioxidants on the healing of foot ulcers in patients with type 2 diabetes mellitus

the intervention group receive 2 x ons drink daily (total 2 x 200 kcal, 3 g arginin, 250 ml vitamin c, 38 mg vitamin e, 64 micr.g selenium, 9 mg zink)

Eligibility criteria:
inclusion criteria: * type 2 diabetes with newly diagnosed foot ulcer * accept study participation exclusion criteria: * hba1c \>90 mmol/l * cognitive challenges, fx dementia * history with known alcohol or drug abuse * allergy to milk or soya * home less * critical ischemia, distal blood pressure \<0.30 * egfr \< 30 * dialysis or planned dialysis or patients with terminal kidney insufficiency
recovery of hibernating myocardium in end stage heart failure

Conditions: Myocardial Function After LVAD Implant; Ischemic Cardiomyopathy

Summary: this study will collect clinical, echocardiographic, nuclear imaging and hemodynamic data in a group of patients with end stage ischemic cardiomyopathy undergoing left ventricular assist device (lvad) implantation to investigate the incidence of recovery of myocardial function when supported with lvads, and to study the association between hibernating myocardium and myocardial recovery in this population.

clinical, echocardiographic and hemodynamic data will be obtained from the patients' medical records. assessment of viability will be performed using a tl-201 rest-redistribution scintigraphy protocol within 2 weeks before lvad implantation and 2 months after lvad implant. recovery of myocardial function will be assessed using available 2d transthoracic echocardiographic images and with the novel imaging modality, speckle tracking echocardiography (ste), in order to provide a regional quantification of the myocardium, in the context of tl-201 results. transthoracic echocardiograms will be performed 2 weeks prior to the lvad implant and 1, 2, 3, 4, 6, 9, and 12 months after implantation.

Eligibility criteria:
inclusion criteria: 1. male or non-pregnant female \>= 18 years of age. 2. end stage chronic and dilated ischemic cardiomyopathy requiring lvad support. 3. ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures. ischemic cardiomyopathy is defined by a lvef \< 40% and any of the following: * history of myocardial infarction or revascularization. * history of angina or chest pain and evidence of scarring in non-invasive imaging studies corresponding to previous myocardial infarction. * presence of ≥ 75% stenosis of the left main or proximal left anterior descending artery, or ≥ 75% stenosis of 2 or more epicardial vessels in a patient with unexplained cardiomyopathy. exclusion criteria: * pregnant and/or lactating women and women of child bearing potential who are not using acceptable means of contraception. women of childbearing potential must be using adequate measures of contraception (as determined by the investigator) to avoid pregnancy and should be highly unlikely to conceive during the study period. women of childbearing potential must have a negative pregnancy test at screen. * patients with acute forms of hf: acute onset of symptoms \< 3 months, no left and right ventricular dilation. * other conditions that in the opinion of the principal investigator may increase risk to the subject and/or compromise the quality of the clinical trial.
evaluation of placental transfusion techniques in prevention of prematurity related complications

Conditions: Premature; Placental Transfusion

Summary: the objective of this study is to evaluate the general course and prognosis associated with different methods of placental transfusion (intact umbilical cord milking, cut- umbilical cord milking and delayed cord clamping) in premature neonates over the first days of life


Eligibility criteria:
* inclusion criteria: 1. premature neonates ≤ 32 weeks gestational age regardless birth weight 2. will be admitted to neonatal intensive care unit in the first day of life of life exclusion criteria: * exclusion criteria: patient with any of the following will be excluded: 1. preterm babies \>32 weeks 2. major congenital anomalies (complex cyanotic heart disease, major central nervous system anomalies). 3. evidence of head trauma causing major intracranial hemorrhage. 5. concern for abruptions, placenta previa or retroplacental hematoma. 6. cord accident, or avulsion at the time of delivery. 7. refusal to perform the intervention by the obstetrician
induction of pluripotent stem cells from human fibroblasts of dm1 patients

Conditions: DM1

Summary: the objective of the study is the modelisation of human cardiomyocyts from pluripotent stem cells in order to study the cardiac alterations induced by ctg expansions.


Eligibility criteria:
inclusion criteria for dm1 patient with cardiomyopathy: * aged 20-50 * dm1 confirmed by molecular analysis * confirmed cardiomyopathy (infrahissiens conduction disorders) * able to sign the consent form * affiliated to european social security. inclusion criteria for dm1 patient without cardiomyopathy * aged 20-50 * dm1 confirmed by molecular analysis * no cardiomyopathy (no infrahissiens conduction disorders or other trouble linked to dm1) * able to sign the consent form * affiliated to european social security. inclusion criteria for controls * aged over 18 * brother, sister, father or mother of the dm1 patient * no dm1 confirmed by molecular analysis (ctg repetition under 38) * no cardiac disorders. * able to sign the consent form * affiliated to european social security. exclusion criteria: * no pragnant or nursing women * patient unable to understand informed consent * patient under juridic protection

Keywords: dm1 cardiopathy adult
german mpn-registry for bcr-abl 1-negative myeloid neoplasms (study group ulm)

Conditions: BCR-ABL1-Negative Myeloid Neoplasms

Summary: to register a large number of patients with the diagnosis of a bcr-abl 1- negative myeloid neoplasm (according to who 2008 / 2016 classification) in participating centers to store samples from all patients (e.g. bone marrow aspirate, peripheral blood, plasma, and buccal swap, skin biopsy samples in exceptional cases) to perform morphologic and genetic analyses to assess clinical characteristics and outcome data using a defined catalogue containing clinically relevant variables to assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers) to assess quality of life

to register a large number of patients with the diagnosis of a bcr-abl 1- negative myeloid neoplasm (according to who 2008 / 2016 classification) in participating centers to store samples from all patients (e.g. bone marrow aspirate, peripheral blood, plasma, and buccal swap, skin biopsy samples in exceptional cases) to perform morphologic and genetic analyses to assess clinical characteristics and outcome data using a defined catalogue containing clinically relevant variables to assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers) to assess quality of life

Eligibility criteria:
inclusion criteria: both female and male patients meeting the mentioned inclusion criteria will be included in this registry, because the risk to get a myeloid neoplasm does not depend on a patient's gender. patients must meet all of the following inclusion criteria to be eligible for enrollment into the registry: * patients with bcr-abl 1-myeloid neoplasia according to who classification or iwg mri criteria * age ≥ 18 years. there is no upper age limit. * signed written informed consent. exclusion criteria: * severe neurological or psychiatric disorder interfering with ability to give an informed consent * no consent for registration, storage and handling of the personal data
tms-induced plasticity improving cognitive control in ocd

Conditions: Obsessive-Compulsive Disorder

Summary: repetitive transcranial magnetic stimulation (rtms) has been shown in several previous clinical trials to be an effective treatment for obsessive-compulsive disorder (ocd). however, the neural working mechanisms of rtms in ocd are unknown, and the optimal stimulation sites have not yet been established. our study aims to compare the clinical and neurobiological effects of three different rtms stimulation protocols in ocd patients. 8 weeks of rtms therapy will be delivered in combination with cognitive behavioural therapy. multimodal neuroimaging will be carried out before and after treatment in order to demonstrate the neurobiological effects of the therapy.


Eligibility criteria:
inclusion criteria: ocd patients: * age between 18 and 65 * primary dsm-5 diagnosis of ocd * moderate to severe ocd symptoms (expressed as a minimum score of 16 on the yale - brown obsessive compulsive scale (ybocs) * unmedicated or stable dose of medication for at least 12 weeks prior to randomisation - with no plans to change dose during the study period * at least 1 previous attempt at cognitive behavioural therapy (cbt) in lifetime * at least 1 previous attempt with serotonergic medication or strong preference for non-pharmacological treatment * capacity to provide informed consent healthy controls (baseline measurements only): * age between 18 and 65 * capacity to provide informed consent exclusion criteria: ocd patients: * mri exclusion criteria (metal in body, pregnancy) * tms exclusion criteria (metal in body, history of epilepsy) * schizophrenia, bipolar disorder, active suicidal ideation, use of antipsychotics within last 12 weeks * previous experience with rtms as treatment healthy controls: * current diagnostic and statistical manual (dsm)-5 diagnosis * personal history of dsm-5 diagnosis * use of psychotropic medications within last 12 months * 1st degree family member with ocd * mri exclusion criteria (as above) * tms exclusion criteria (as above)